Back to IMVTView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Chronic Inflammatory Demyelinating Polyneuropathy
View Full LandscapeDrug Information
Target Indication
Chronic Inflammatory Demyelinating Polyneuropathy
Clinical Trial
NCT07032662Last updated: 1/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
BatoclimabPhase 3
Thyroid Eye Disease
Batoclimab 680 mg SC weeklyPhase 3
Generalized Myasthenia Gravis
Batoclimab 680 milligrams (mg) subcutaneous (SC) weeklyPhase 2
Chronic Inflammatory Demyelinating Polyneuropathy
RVT-1401Phase 2
Myasthenia Gravis
IMVT-1401 (batoclimab)Phase 2
Graves Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts